SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

AstraZeneca Pharma India informs about appointment of senior management personnel

15 Sep 2023 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, AstraZeneca Pharma India has informed that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Praveen Akkinepally as the Business Unit Head – Oncology with effect from November 1, 2023. Praveen will be part of the Senior Management team of the Company. In this regard, the company has enclosed the details as required under the SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 as Annexure – A.

The above information is a part of company’s filings submitted to BSE.


Astrazeneca Pharma I Share Price

8530.00 21.20 (0.25%)
20-Apr-2026 14:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.15
Dr. Reddys Lab 1234.30
Cipla 1232.95
Zydus Lifesciences 938.40
Lupin 2329.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×